Next-Generation Immunology Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Next-Generation Immunology Drugs Market is segmented by Drug Class (Small Molecules, Antibodies, Cell-Based Therapies, Others), Therapeutic Area (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Others), Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The report offers the value in USD million for the above segments.

Next-Generation Immunology Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Next-Generation Immunology Drugs Market Size

Next-Generation Immunology Drugs Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
CAGR 6.10 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Next-Generation Immunology Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Next-Generation Immunology Drugs Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Next-Generation Immunology Drugs Market Analysis

The Next-Generation Immunology Drugs Market is expected to register a CAGR of 6.1% during the forecast period.

The COVID-19 pandemic had a significant impact on the market studied. During the pandemic, immunology research was increased to understand the effects of COVID-19 on immunity and cope with the severe effects of the same. For instance, the University of Oxford Immunology Network conducted research on COVID-19 in early 2021 that was focused on humoral immunity, deep phenotyping, the inflammatory response, and cell immunity. Additionally, research in the area of immunology drugs for COVID-19 increased during the pandemic. For instance, JAK and BTK inhibitors were immunomodulatory drugs that were evaluated to treat COVID-19. GM-CSF Inhibitors. The rising research on immunology drugs to combat the COVID-19 disease fueled the market's growth. However, currently, the market has reached its pre-pandemic nature and is expected to witness significant growth over the forecast period.

Some of the key factors propelling market growth include the rising burden of chronic diseases, increasing research in the area of next-generation drugs, and an increased focus on targeted therapies for certain diseases.

The market for next-generation immunology drugs is expected to witness a healthy growth due to the rising prevalence of chronic diseases like asthma, allergic conditions, cancer, and multiple sclerosis. For instance, a January 2023 report from the American Cancer Society indicated that by the year 2040, there will be more than 16.3 million cancer-related deaths and over 27.5 million new cases worldwide due to population growth and aging. The burden will probably increase in the future because risk factors including smoking, eating poorly, and not exercising are becoming more prevalent in economically developing countries. With growing chronic diseases, pharmaceutical companies are focusing more on R&D and developing novel drugs, which is contributing to market growth.

Furthermore, the key activities undertaken by the various companies are supporting market growth. For instance, in November 2022, Human Immunology Biosciences announced that it had raised USD 120 million to develop targeted treatments for autoimmune and allergic diseases. The company developed two drug candidates, called felzartamab and HIB210, that were licensed from the German biotechnology company MorphoSys. Both are in clinical trials, with the former in Phase 2 testing for two rare kidney diseases and the latter in Phase 1. Hence, owing to the increasing focus of companies on developing such novel drugs, it is believed that the market studied is likely to witness strong growth. However, the high cost of next-generation drugs and stringent regulatory policies are some of the factors that are expected to restrain market growth.

Next-Generation Immunology Drugs Industry Overview

The next-generation immunology drugs market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The market players are focusing on new product launches, R&D, and expansions to gain a competitive advantage. Some of the market's major players include AbbVie Inc., Amgen Inc., AstraZeneca, GlaxoSmithKline PLC, Novartis AG, and F. Hoffmann-La Roche AG.

Next-Generation Immunology Drugs Market Leaders

  1. AbbVie

  2. Novartis AG

  3. GSK plc

  4. Pfizer Inc.

  5. Bristol-Myers Squibb Company

  6. *Disclaimer: Major Players sorted in no particular order
Next Generation Immunology Drugs Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Next-Generation Immunology Drugs Market News

  • November 2022: DuoBody-PD-L1x4-1BB (GEN1046) monoclonal antibody was co-developed by Genmab and BioNTech for Solid tumors in Phase 1/2 and Non-small cell lung cancer in Phase 2.
  • October 2022: the FDA approved a combination of the immunotherapy drugs durvalumab (Imfinzi) and tremelimumab (Imjudo) for people with unresectable hepatocellular cancer, the most common type of liver cancer.

Next-Generation Immunology Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Chronic Diseases
    • 4.2.2 Increasing Research in the Area of Next Generation Drugs
    • 4.2.3 Increasing Focus on Targeted Therapies
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Next Generation Drugs
    • 4.3.2 Stringent Regulatory Policies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Small Molecules
    • 5.1.2 Antibodies
    • 5.1.3 Cell Based Therapies
    • 5.1.4 Other Drug Classes
  • 5.2 By Therapeutic Area
    • 5.2.1 Cancer
    • 5.2.2 Autoimmune Diseases
    • 5.2.3 Infectious Diseases
    • 5.2.4 Inflammatory Diseases
    • 5.2.5 Other Therapeutic Areas
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Pfizer Inc
    • 6.1.2 Abbvie Inc.
    • 6.1.3 Johnson and Johnson
    • 6.1.4 F. Hoffmann-La Roche Ltd.
    • 6.1.5 Amgen Inc.
    • 6.1.6 Novartis AG
    • 6.1.7 Astellas Pharma Inc.
    • 6.1.8 UCB SA
    • 6.1.9 Bristol-Myers Squibb Company
    • 6.1.10 Merck & Co., Inc.
    • 6.1.11 Eli Lilly and Company
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Next-Generation Immunology Drugs Industry Segmentation

As per the scope of this report, next-generation immunology drugs refers to a new class of medications that are designed to modulate the immune system in a more targeted and precise way compared to traditional immunomodulatory drugs. The Next-Generation Immunology Drugs Market is segmented by Drug Type (Small Molecules, Antibodies, Cell-Based Therapies, Others), Therapeutic Area (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value in USD million for the above segments.

By Drug Class Small Molecules
Antibodies
Cell Based Therapies
Other Drug Classes
By Therapeutic Area Cancer
Autoimmune Diseases
Infectious Diseases
Inflammatory Diseases
Other Therapeutic Areas
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Next-Generation Immunology Drugs Market Research FAQs

What is the current Next-Generation Immunology Drugs Market size?

The Next-Generation Immunology Drugs Market is projected to register a CAGR of 6.1% during the forecast period (2025-2030)

Who are the key players in Next-Generation Immunology Drugs Market?

AbbVie, Novartis AG, GSK plc, Pfizer Inc. and Bristol-Myers Squibb Company are the major companies operating in the Next-Generation Immunology Drugs Market.

Which is the fastest growing region in Next-Generation Immunology Drugs Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Next-Generation Immunology Drugs Market?

In 2025, the North America accounts for the largest market share in Next-Generation Immunology Drugs Market.

What years does this Next-Generation Immunology Drugs Market cover?

The report covers the Next-Generation Immunology Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Next-Generation Immunology Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Next-Generation Immunology Drugs Industry Report

Statistics for the 2025 Next-Generation Immunology Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Next-Generation Immunology Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.